 |
14 Diseases |  |
33 Trials |
|
33 Trials |  |
2608 News |  |
| «12345678910111213...3132» |
- | teriflunomide / Generic mfg.
Preclinical, Journal: Surgically Induced Demyelination in Rat Sciatic Nerve. (Pubmed Central) - May 27, 2023
Further, administration of Teriflunomide (TF) to p-SNI rats resulted in the restoration of motor function, repair of axonal atrophies with inter-axonal spaces, and myelin secretion or remyelination. Taken together, our findings demonstrate a surgical procedure that can induce demyelination in the rat sciatic nerve, which is then remyelinated after TF treatment.
- | teriflunomide / Generic mfg.
Journal, HEOR: Assessing the Health Economic Outcomes from Commercially Insured Relapsing Multiple Sclerosis Patients Who Switched from Other Disease-Modifying Therapies to Teriflunomide, in the United States. (Pubmed Central) - May 26, 2023
Switching to teriflunomide from existing DMTs in patients with relapsing MS resulted in a reduction in outpatient HCRU in this analysis of US claims data. The real-world effectiveness of teriflunomide was generally consistent with efficacy reported in clinical trials, showing a reduction in relapse following a switch to teriflunomide.
- | Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Journal: The Impact of SARS-CoV-2 Infection in Multiple Sclerosis Patients taking Disease- Modifying Therapies. (Pubmed Central) - May 26, 2023
B-cell depleting agents (ocrelizumab and rituximab) were given to 19 patients, another 19 were on immune cell Traffickers (fingolimod and natalizumab) and 13 were on other DMT treatments (alemtuzumab, cladribine, interferon-beta, dimethyl fumarate, and teriflunomide)...None experiences MS relapses during infection. Two patients on rituximab had a moderate course of the illness, which required hospitalization for oxygen support, but did not need mechanical ventilation and the rest remained asymptomatic.
- | Journal, Adherence: Comparative adherence trajectories of oral disease-modifying agents in multiple sclerosis. (Pubmed Central) - May 9, 2023
TER and DMF were associated with poorer adherence trajectories than FIN. More research is needed to evaluate the clinical implications of these adherence trajectories of oral DMAs to optimize the management of MS.
- | teriflunomide / Generic mfg.
Biomarker, Enrollment open: RESEPTOR 5-HT7: Implication of 5-HT7 Receptor in Inflammatory Mechanisms in Multiple Sclerosis (clinicaltrials.gov) - May 6, 2023
P=N/A, N=120, Recruiting, Sponsor: Centre Hospitalier R
More research is needed to evaluate the clinical implications of these adherence trajectories of oral DMAs to optimize the management of MS. Not yet recruiting --> Recruiting
- | Tysabri (natalizumab) / Biogen, Royalty
Observational data, Retrospective data, Journal: The impact of disease-modifying therapies on immunoglobulin blood levels in patients with multiple sclerosis: a retrospective cross-sectional study. (Pubmed Central) - Apr 28, 2023
Treatment with dimethyl fumarate (DMF) and teriflunomide was associated with lower IgG, but not IgM levels...Treatment with interferon-beta (IFN) and glatiramer acetate (GA) had no impact on Ig levels...DMTs differed in the extent of decreasing Ig levels but also in their differential effects on Ig subclasses. Monitoring of Ig levels should be considered in patients on long-term treatment with DMTs, particularly those on BCDT, to identify patients at risk of low immunoglobulin levels.
- | teriflunomide / Generic mfg.
Preclinical, Journal: A Dual Therapy of Nanostructured Lipid Carrier Loaded with Teriflunomide-A Dihydro-Orotate Dehydrogenase Inhibitor and an miR-155-Antagomir in Cuprizone-Induced C57BL/6J Mouse. (Pubmed Central) - Apr 28, 2023
Our findings have significant implications for the future development of nanocarrier-based therapies and personalized medicine. Our results provide a strong foundation for further studies and the potential to develop safe and economic therapeutics for CNS disorders.
- |||||| teriflunomide / Generic mfg.
Clinical: Done! TERIS Study results has been presented at the @AANmember #AAN2023 Teriflunomide reduces risk of MS compared to placebo in RIS. #RISConsortium @CHUdeNice #UTSW @MayoClinic @sanofi (Twitter) - Apr 28, 2023
- || divozilimab (BCD-132) / Biocad
Clinical, Clinical Trial,Phase II, Journal: Efficacy and safety of divozilimab during 24-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-2 (Pubmed Central) - Apr 25, 2023
Thus, the assessment of 24 weeks treatment demonstrated that DIV is a highly effective, safe and convenient option for the treatment of RRMS patients, both naive and previously treated with disease modifying therapy. A dose of 500 mg is recommended for further efficacy and safety evaluation during phase 3 CT.
- | dimethyl fumarate / Generic mfg.
New trial: Effects of Dimethyl Fumarate on Cognitive Performance and Brain Abnormalities in Multiple Sclerosis. (clinicaltrials.gov) - Apr 13, 2023
P=N/A, N=52, Recruiting, Sponsor: IRCCS Centro Neurolesi "Bonino-Pulejo"
- | Lemtrada (alemtuzumab) / Sanofi
Journal: In-depth characterization of long-term humoral and cellular immune responses to COVID-19m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumab. (Pubmed Central) - Apr 11, 2023
MS patients treated with teriflunomide or alemtuzumab achieved effective humoral and cellular immune responses up to 6 months following second COVID-19 vaccination. Immune responses were reinforced following the third vaccine booster.
- | fingolimod / Generic mfg.
Journal: Increased NLRP3 Inflammasome Activation and Pyroptosis in Patients With Multiple Sclerosis With Fingolimod Treatment Failure. (Pubmed Central) - Mar 28, 2023
Immune responses were reinforced following the third vaccine booster. The differential effect of fingolimod on the formation of an inflammasome-triggered ASC oligomer in monocytes between responders and nonresponders could be used as a response biomarker after 6 months of fingolimod treatment and suggests that fingolimod may exert their beneficial effects by reducing inflammasome signaling in a subset of patients with MS.
- | moclobemide / Generic mfg., teriflunomide / Generic mfg.
Journal: Amidation by reactive extrusion for the synthesis of active pharmaceutical ingredients teriflunomide and moclobemide. (Pubmed Central) - Mar 24, 2023
The solventless synthesis of an amide was performed in a twin-screw extruder in the presence of a coupling agent, providing a high yielding and productive method. The reaction conditions were optimized to prepare APIs, teriflunomide and moclobemide.
- | teriflunomide / Generic mfg.
Trial completion: TERICIS: A Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension Period (clinicaltrials.gov) - Mar 22, 2023
P3, N=5, Completed, Sponsor: Centre Hospitalier Universitaire de Nice
The reaction conditions were optimized to prepare APIs, teriflunomide and moclobemide. Unknown status --> Completed
- |||||| teriflunomide / Generic mfg.
New trial: KRONOS: Early Versus Late Ofatumumab (Kesimpta (clinicaltrials.gov) - Mar 20, 2023
P=N/A, N=100, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- ||||| teriflunomide / Generic mfg.
Trial completion: TERIS: Randomized, Double-blinded Study of Treatment:Teriflunomide, in Radiologically Isolated Syndrome (clinicaltrials.gov) - Mar 17, 2023
P3, N=125, Completed, Sponsor: Centre Hospitalier Universitaire de Nice
Unknown status --> Completed Active, not recruiting --> Completed
- | Mavenclad (cladribine) / EMD Serono
Preclinical, Journal: Using an animal model to predict the effective human dose for oral multiple sclerosis drugs. (Pubmed Central) - Mar 16, 2023
Active, not recruiting --> Completed Although initial proof-of-concept studies of oral fingolimod tested the efficacy and safety of 1.25 and 5
- | teriflunomide / Generic mfg., leflunomide / Generic mfg.
Journal: Therapeutic drug monitoring of teriflunomide: do plasma concentrations predict response to leflunomide in patients with rheumatoid arthritis? (Pubmed Central) - Mar 16, 2023
We did not find a concentration-effect-relationship. However, therapeutic drug monitoring of teriflunomide may be useful to ensure adherence and evaluate toxic-levels in case of adverse-events.
- | teriflunomide / Generic mfg.
Trial primary completion date: TERIPET: Effect of Teriflunomide Treatment on Microglial Activation in an MS Patient Cohort at Risk of Progression (clinicaltrials.gov) - Mar 16, 2023
P=N/A, N=26, Active, not recruiting, Sponsor: Turku University Hospital
However, therapeutic drug monitoring of teriflunomide may be useful to ensure adherence and evaluate toxic-levels in case of adverse-events. Trial primary completion date: Nov 2022 --> Dec 2023
- | Lemtrada (alemtuzumab) / Sanofi
Journal: Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis. (Pubmed Central) - Mar 15, 2023
Trial primary completion date: Nov 2022 --> Dec 2023 The use of AHSCT in people with active SPMS is associated with a slowing of disability progression and a higher likelihood of disability improvement compared with standard immunotherapy.
- | Journal, HEOR: Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity. (Pubmed Central) - Mar 14, 2023
The use of AHSCT in people with active SPMS is associated with a slowing of disability progression and a higher likelihood of disability improvement compared with standard immunotherapy. Patients with RRMS switching from BRACETD demonstrated better outcomes with natalizumab than with fingolimod.
- | teriflunomide / Generic mfg.
Retrospective data, Journal, Real-world evidence, Real-world: Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis. (Pubmed Central) - Mar 14, 2023
Our multicenter, longitudinal, retrospective study demonstrated that patients with RMS aged 55 or older switching to teriflunomide from other DMTs had significantly improved ARR, stable disability, and stable or improved MRI over up to 2 years' follow up. Safety results were acceptable with fewer patients exhibiting lymphopenia at years 1 and 2 post-index.
- |||||| Vumerity (diroximel fumarate) / Biogen
New trial: A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS) (clinicaltrials.gov) - Mar 14, 2023
P=N/A, N=10500, Not yet recruiting, Sponsor: Biogen
- Lemtrada (alemtuzumab) / Sanofi
Real-world effectiveness of switching treatment after initial platform injectable disease-modifying therapies in pediatric multiple sclerosis in the US (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_4196;
Design/Methods This is a cohort study of pediatric MS/CIS at 12 clinics in the US Network of Pediatric MS Centers, who received initial therapy with platform injectable (interferon-?, glatiramer acetate) and switched to other injectable, oral (dimethyl fumarate, fingolimod, teriflunomide) or infusion (natalizumab, rituximab, ocrelizumab, alemtuzumab) DMT...Conclusions Switching from platform injectable to oral or infusion vs another injectable DMT led to better disease activity control of pediatric MS. Long-term safety data for oral and infusion DMTs are required.
- Mavenclad (cladribine) / EMD Serono
Patient Characteristics and Persistence Among Commercially Insured Patients With Multiple Sclerosis Initiating Cladribine Tablets (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_4189;
Overall persistence was 93.0%, and mean (SE) survival time until first evidence of nonpersistence was 215.2 (3.2) days. Conclusions In the 1 year after CladT initiation, nearly all patients completed their first CladT treatment cycle, and few switched to another DMT.
- Mayzent (siponimod) / Novartis
AMA-VACC: Clinical trial assessing the immune response to SARS-CoV-2 mRNA vaccines and booster vaccination in siponimod treated patients with secondary progressive multiple sclerosis (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_3858;
Results After a positive first interim analysis showing both SARS-CoV-2 neutralizing antibodies and T-cell responses one week after complete vaccination in siponimod patients, final data of the study will be available in early 2023 including the effect of booster vaccination, which was received by 38 of 41 patients during study. Conclusions This final analysis of the AMA-VACC trial will provide first longitudinal data on the immune response after SARS-CoV-2 mRNA vaccination and booster vaccination in siponimod treated SPMS patients and support physicians and patients to make an informed decision on the coordination of SARS-CoV-2 mRNA vaccination and SPMS treatment.
- teriflunomide / Generic mfg.
Exploring New Imaging Biomarkers: 3D Conformational Analysis Of The Medulla And Upper Cervical Spinal Cord In People With Relapsing Multiple Sclerosis (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_3527;
P3
In the placebo-controlled Phase 3 TEMSO trial (NCT00134563), teriflunomide 14 mg/day lowered the risk of disability worsening and reduced brain volume loss in participants with relapsing MS...Conclusions 3D conformational analysis of MP-RAGE images from the TEMSO trial showed no discernable between-group differences for MUCSC surface features or volume; however, imbalanced exclusion of participants during quality assessment likely introduced attrition bias. Further development of 3D conformational metrics as MS biomarkers may better illuminate mechanisms related to neurodegenerative changes and treatment efficacy.
- teriflunomide / Generic mfg.
Teriflunomide (Aubagio) Extends The Time To Multiple Sclerosis In Radiologically Isolated Syndrome: The TERIS Study. (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_3155;
Further development of 3D conformational metrics as MS biomarkers may better illuminate mechanisms related to neurodegenerative changes and treatment efficacy. Background Objective Design/Methods Results Conclusions
- Lemtrada (alemtuzumab) / Sanofi
A 2-Stage Model of Heterogenous Treatment Effects for Brain Atrophy in MS Utilizing the MS PATHS Research Network (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_3028;
Conclusions HTE models suggest individuals with low baseline risk of brain atrophy may achieve similar outcomes regardless of DMT efficacy choice. The worst relative outcomes occur when patients with high brain atrophy risk are treated with low-efficacy DMTs.
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
Five-Year Safety of Ofatumumab in People Living With Relapsing Multiple Sclerosis (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_2824;
We previously reported cumulative safety data for up to 4 years of ofatumumab treatment in the overall (N=1969), continuous (ofatumumab in core+extension; N=1292) and newly-switched (teriflunomide in core/ofatumumab in extension; N=677) groups...Conclusions Previously reported safety findings for up to 4 years showed ofatumumab treatment to be well tolerated with no new safety risks identified. Additional safety data for up to 5 years will help inform physicians on the longer-term safety profile of ofatumumab in people living with RMS.
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
Compliance and Persistence With Ofatumumab Treatment in Patients With Relapsing Multiple Sclerosis in Clinical Trials for Up to 4 Years (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_2822;
P2, P3
Conclusions High compliance was observed with monthly subcutaneous ofatumumab (~95% across core and open-label extension studies). A small proportion of patients discontinued ofatumumab, indicating high treatment persistence.
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
Efficacy of Early Ofatumumab vs Late Switch From Teriflunomide: Subgroup Analysis of the ALITHIOS Open-label Extension Study by Previous Disease-Modifying Therapy Exposure and Age (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_2484;
P3
Incidence of adverse events was consistent with ASCLEPIOS I/II. Conclusions Switching from TER to OMB reduced clinical and MRI disease activity across all previous DMT and age subgroups, particularly for younger patients and those treated with ?1 DMT, highlighting the importance of earlier treatment initiation.
- Briumvi (ublituximab) / TG Therap
Ublituximab Efficacy in Treatment-Naive Participants With Relapsing Multiple Sclerosis in the Phase 3 ULTIMATE I and II Studies (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_2483;
Occurrence of 12-week confirmed disease progression was low in both treatment groups. Conclusions In pooled post hoc analyses of ULTIMATE I and II, ublituximab was associated with significant treatment benefit across multiple efficacy measures at Week 96 versus teriflunomide in participants who had not received prior DMT.
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
Long-term Effect of Ofatumumab Treatment on Serum Neurofilament Light Chain Levels and NEDA-3 Status in Patients With RMS: Results From ASCLEPIOS I/II and ALITHIOS (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_2481;
P3
Objective To assess the long-term effect of ofatumumab (OMB; anti-CD20 monoclonal antibody) on serum neurofilament light chain (sNfL) levels and 3-parameter no evidence of disease activity (NEDA-3) in patients with relapsing multiple sclerosis receiving continuous OMB and those converted from teriflunomide (TER) in ASCLEPIOS I/II (core; NCT02792218/NCT02792231) and ALITHIOS (open-label extension; NCT03650114)...NEDA-3 achievement during Y2 was similar in OMB-OMB and TER-OMB (86.4% vs 90.4%; 1.55 [1.07-2.22]; p=0.019). Conclusions A near complete and sustained suppression of disease activity was achieved with early and continuous use of OMB, and a rapid reduction in disease activity followed conversion from TER to OMB.
- fingolimod / Generic mfg.
Final results of the PANGAEA 2.0 study: Treatment benefits of fingolimod for active RRMS patients switching from other DMTs (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_2477;
Conclusions A near complete and sustained suppression of disease activity was achieved with early and continuous use of OMB, and a rapid reduction in disease activity followed conversion from TER to OMB. To obtain insight into the effectiveness of changing to fingolimod, subgroup analyses were based on the patients
- Ponvory (ponesimod) / J&J
Longitudinal Clinical and MRI Outcomes in Relapsing Multiple Sclerosis (RMS) Patients After Short-term Ponesimod Treatment Interruption and Re-initiation (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_2475;
At OLE week 48, patients had 1.73 CUALs/year (95% CI:1.30, 2.31), which was not statistically significantly different from 1.48 CUALs/year (95% CI: 1.19, 1.82) in OPTIMUM. Conclusions Based on clinical and imaging outcomes at 48 weeks following short-term interruption and re-initiation of ponesimod, disease activity remained consistent with that observed prior to interruption.
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
Improvement in Cognitive Processing Speed With Ofatumumab in Patients With Relapsing Multiple Sclerosis (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_2473;
P3
Conclusions Ofatumumab was associated with more clinically meaningful improvements in CPS vs teriflunomide in both populations. Early initiation of ofatumumab may enhance CPS improvement in patients with RMS by suppressing inflammation.
- teriflunomide / Generic mfg.
Comparison of 2-year Teriflunomide Outcomes between DMT-naive and switch patients with Relapsing MS: subanalysis of the Real-World TERICARE study (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_2472;
DMT-naive experienced a greater and significant reduction (improvement) in psychological MSIS-29 score at month 24 compared to switch group (-7.11 vs -1.48; p=0.019). Conclusions Teriflunomide shows effectiveness in both DMT-naive and switch RRMS patients with a trend towards better relapse and quality of life outcomes in DMT-naive.
- Briumvi (ublituximab) / TG Therap
Disease Outcomes With Ublituximab in Participants With Highly Active Disease: Subpopulation Analyses of the Phase 3 ULTIMATE I and II Studies in Participants With Relapsing Multiple Sclerosis (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_2471;
The occurrence of 12-week confirmed disability progression was low in both treatment groups (8.0% ublituximab; 5.0% teriflunomide). Conclusions In pooled post hoc analyses of ULTIMATE I and II, ublituximab was associated with significant treatment benefit across multiple efficacy measures at Week 96 versus teriflunomide in participants with highly active disease at baseline.
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
Effect of Longer-term Ofatumumab Treatment on Disability Progression and Brain Volume Change (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_2291;
Background In the ASCLEPIOS I/II core studies, ofatumumab (3-/6-month[m] CDW: 10.90%/8.15%) delayed disability accrual compared with teriflunomide (3/6mCDW: 14.98%/11.95%)...Conclusions With longer-term ofatumumab treatment, disability progression was predominantly PIRA, the annual rate of BVC remained low, and low rates of CDW/PIRA indicated that most patients remained free from disease progression. Outcomes favored early, compared with later, initiation with ofatumumab.
- | New trial, Real-world evidence, Real-world: CPE: Czech Pharmaco-epidemiological Study on Disease Modifying Drugs (clinicaltrials.gov) - Mar 9, 2023
P=N/A, N=17478, Completed, Sponsor: IMPULS Endowment Fund
- Ocrevus (ocrelizumab) / Roche, Biogen
Cost-Effectiveness of Ocrelizumab Compared with Dmt for the Treatment of Relapsing-Remitting Multiple Sclerosis in Czech Republic () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_2110;
Ocrelizumab was not cost-effective on the applied threshold level of approx. $51,000 with official price.
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
Comparative Clinical Effectiveness of Monoclonal Antibodies for the Treatment of Relapsing Multiple Sclerosis: A Systematic Review and Network Meta-Analysis () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_973;
The benefits of treatment on CDP-3/6 are less certain. There is insufficient evidence to establish whether there are differences in clinical effectiveness amongst the monoclonal antibodies.
- Ocrevus (ocrelizumab) / Roche, Biogen
Cost-Effectiveness of Ocrelizumab in First-Line Treatment of Highly Active Relapsing-Remitting Multiple Sclerosis in Chile () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_761;
OBJECTIVES: To develop a cost-effectiveness analysis of ocrelizumab versus other first-line treatment alternatives (interferons, dimethyl fumarate, glatiramer acetate, teriflunomide, and fingolimod) for highly active relapsing-remitting multiple sclerosis from the perspective of the Chilean public health system... Ocrelizumab is a cost-effective alternative for treating patients with highly active relapsing-remitting multiple sclerosis in the Chilean setting as first-line treatment.
- || teriflunomide / Generic mfg.
teriflunomide (Twitter) - Mar 8, 2023
- ||| teriflunomide / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: AUBACOG: Cognition and MRI Markers in MS Patients With Aubagio (clinicaltrials.gov) - Mar 8, 2023
P=N/A, N=75, Completed, Sponsor: University Hospital, Bordeaux
Ocrelizumab is a cost-effective alternative for treating patients with highly active relapsing-remitting multiple sclerosis in the Chilean setting as first-line treatment. Active, not recruiting --> Completed | Trial completion date: Nov 2022 --> Feb 2023 | Trial primary completion date: Nov 2022 --> Feb 2023
- | Plegridy (PEG-interferon ?-1a) / Biogen, teriflunomide / Generic mfg.
Journal: Recurrent encephalopathy associated with pegylated beta-interferon treatment. (Pubmed Central) - Mar 7, 2023
Active, not recruiting --> Completed | Trial completion date: Nov 2022 --> Feb 2023 | Trial primary completion date: Nov 2022 --> Feb 2023 These episodes occurred about 3
- | Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Briumvi (ublituximab) / TG Therap, Mavenclad (cladribine) / EMD Serono
Journal: Ublituximab (Briumvi) for relapsing multiple sclerosis. (Pubmed Central) - Mar 7, 2023
These episodes occurred about 3 No abstract available
- | glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg., teriflunomide / Generic mfg.
Journal: Multiple sclerosis and glatiramer acetate: Risk factors for central retinal vein occlusion? (Pubmed Central) - Mar 6, 2023
To the best of our knowledge, no ophthalmologic side effects have been reported with glatiramer acetate. We present a woman with multiple sclerosis on glatiramer acetate therapy with a central retinal vein occlusion in the absence of other risk factors.
- |||| fenebrutinib (GDC-0853) / Roche
Trial completion date, Trial primary completion date: FENhance: A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) (clinicaltrials.gov) - Mar 6, 2023
P3, N=736, Recruiting, Sponsor: Hoffmann-La Roche
We present a woman with multiple sclerosis on glatiramer acetate therapy with a central retinal vein occlusion in the absence of other risk factors. Trial completion date: Feb 2026 --> Nov 2025 | Trial primary completion date: Dec 2025 --> Oct 2025